Key facts
- This page summarizes James R. Sulat's Form 4 filing for Arch Therapeutics, Inc. (ARTHQ).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Oct 2021, 08:14.
James R. Sulat - 27 Sep 2021 Form 4 Insider Report for Arch Therapeutics, Inc. (ARTHQ)
- Reporting relationship
- Director
- Issuer ticker
- ARTHQ
- Reported as of
- 27 Sep 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Oct 2021, 08:14:36 UTC
- Prior SEC filing
- 04 Jun 2021
- Next SEC filing
- 15 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Sulat
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James R. Sulat filed Form 4 for Arch Therapeutics, Inc. (ARTHQ) on 01 Oct 2021.
Change
- Previous filing in this sequence was filed on 04 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ARTH
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 27 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.1028
- Footnotes
- F1
ARTH
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +250,000
- Change %
- Price
- $0.000000
- Shares after
- 250,000
- Date
- 27 Sep 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 250,000
- Exercise price
- $0.1028
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
James R. Sulat is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The option was granted pursuant to the Issuer's 2013 Stock Incentive Plan (the "Plan"). The option shall vest equally on each of the first 36 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.
Footnote F2
The option was granted pursuant to the Plan. 1/3 of the option vested on the grant date and the remainder of the option shall vest equally on each of the first 24 month anniversaries of the grant date, subject to continued service to the Issuer through each vesting date. In the event of a Change of Control (as such term is defined in the Plan), 100% of the number of unvested shares then subject to the option shall accelerate and become immediately exercisable.